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Abstract
Objectives: Many studies have evaluated the ways in which sleep disturbances may influence inflammation and the
possible links of this effect to cardiovascular risk. Our objective was to investigate the effects of chronic sleep restriction and
recovery on several blood cardiovascular biomarkers.
Methods and Results: Nine healthy male non-smokers, aged 22–29 years, were admitted to the Sleep Laboratory for 11
days and nights under continuous electroencephalogram polysomnography. The study consisted of three baseline nights of
8 hours sleep (from 11 pm to 7 am), five sleep-restricted nights, during which sleep was allowed only between 1 am and 6
am, and three recovery nights of 8 hours sleep (11 pm to 7 am). Myeloperoxidase-modified low-density lipoprotein levels
increased during the sleep-restricted period indicating an oxidative stress. A significant increase in the quantity of slow-
wave sleep was measured during the first recovery night. After this first recovery night, insulin-like growth factor-1 levels
increased and myeloperoxidase concentration peaked.
Conclusions: We observed for the first time that sleep restriction and the recovery process are associated with differential
changes in blood biomarkers of cardiovascular disease.
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Introduction
The National Sleep Foundation report indicates that 43% of the
American population sleep less than 7 hours on work days,
compared with 30% during the weekend [1]. This report also
shows that sleep duration increases during the week-end, creating
a possible recovery effect after five consecutive working days of
shorter sleep duration (20% of adults report sleeping less than 6 h/
night). Increasing epidemiologic evidence indicates that sleep
deprivation is associated with an increased risk of cardiovascular
events [2]. In a laboratory study, Van Leeuwen et al. [3] showed
that 5 nights of sleep restriction (4 h) increased the production
of proinflammatory molecules, such as interleukin (IL)-1b, IL-6,
IL-17 and high sensitivity C-reactive protein (hs-CRP). It is
noteworthy that the levels of these molecules remained elevated
after 2 nights of recovery sleep. Recently, we confirmed the inter-
actions between sleep and the immune system [4]. An increase in
peripheral blood leukocyte count was observed after acute sleep
restriction (2 h of sleep), which persisted after a recovery night. In
addition, a short midday nap prior to the recovery night or an
extended night of recovery sleep normalized this increase.
Interestingly, an increase in plasma myeloperoxidase (MPO), an
enzyme that catalyzes oxidation reactions via the release of reactive
halogenating and nitrating species, was also observed after acute
sleep restriction.
It is well known that biomarkers of oxidative stress accurately
reflect the presence of cardiovascular risk, the extent of cardio-
vascular disease (CVD), and cardiovascular outcome. MPO and
modified low density lipoprotein (LDL) are examples of such
biomarkers [5]. On this background, we studied leukocyte subsets,
fibrinogen, hs-CRP, MPO [6–7], MPO-modified LDL (Mox-
LDL) and IL-8 [8], in nine healthy subjects during a protocol of
chronic sleep restriction and recovery for 11 consecutive days and
nights.
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Effects of sleep restriction and recovery on sleep
architecture
The amounts of stage 2 and REM sleep were significantly
reduced during all sleep restricted nights vs. baseline [Chi-square
(6)=27.7, p,0.001 and Chi-square (6)=30.3, p,0.001, respec-
tively; Table 1] and vs. the 3
rd baseline night [Chi-square
(6)=14.4, p=0.01 and Chi-square (6)=30.2, p,0.001, respec-
tively; Table S1]. During sleep restricted nights 1 to 4, there was
a decrease in the percentage of stage 2 sleep with a concomitant
increase in the percentage of slow-wave sleep (SWS) vs. baseline
[Chi-square (6)=15.7, p=0.04 and Chi-square (6)=8.4,
p=0.03, respectively] and vs. the 3
rd baseline night [Chi-square
(6)=8.0, p=0.01 and Chi-square (6)=18.4, p=0.01, respective-
ly]. On the first recovery night, there was a significant increase in
the quantity of SWS when compared to baseline [Chi-square
(6)=15.1, p=0.01] and to the 3
rd baseline night [Chi-square
(6)=11.4, p=0.01]. Sleep efficiency was significantly higher from
the 3
rd sleep restricted night to the first recovery night as
compared to baseline [Chi-square (6)=17.3, p=0.004] and to
the 3
rd baseline night [Chi-square (6)=14.4, p=0.01]. Total
sleep time was reduced during the sleep restricted nights and
increased during the first recovery night vs. baseline [Chi-square
(6)=17.6, p=0.003] and vs. the 3
rd baseline night [Chi-square
(6)=22.0, p=0.001].
Leukocyte, fibrinogen and hs-CRP
Leukocyte counts and leukocyte subsets (neutrophils, lympho-
cytesandmonocytes)remained constant throughoutthe experiment
(Table 2, Table S2). There were no statistically significant changes
in the concentrations of hs-CRP or fibrinogen during the sleep
restriction or recovery periods.
MPO, Mox-LDL, IL-8 and IGF-1
The levels of Mox-LDL were significantly increased during the
first and third days of sleep restriction compared to the baseline
level [Chi-square (6)=20.9, p=0.002] (Table 2) and to the level
after the 3
rd baseline night [Chi-square (6)=20.52, p=0.002;
Table S2]. Interestingly, no change in ApoB concentration was
observed during the sleep restricted phase. ApoB significantly
decreased after the last night of recovery sleep compared to the
baseline level [Chi-square (6)=17.1 p=0.007] and to the level
after the 3
rd baseline night [Chi-square (6)=16.54, p=0.01].
The Mox-LDL/ApoB ratio (an estimation of the proportion of
MPO modified-LDL in the bloodstream) was markedly increased
during the 1
st and 3
rd days of sleep restriction compared to the
baseline level [Chi-square (6)=12.7, p=0.04] (Fig. 1A) and to the
level after the 3
rd baseline night [Chi-square (6)=13.1, p=0.03].
MPO concentration reached a peak after the first recovery night
compared to the baseline concentration (69.3 [34.1–98.6] ng/ml
versus 29.4 [25.3–57.2] ng/ml respectively, Chi-square (6)=20.5,
p=0.002) (Fig. 1B) and to the concentration after the 3
rd baseline
night [Chi-square (6)=20.37, p=0.002]. There was no significant
change in IL-8 levels during the protocol compared to the baseline
level [Chi-square (6)=10.3, p=0.11] or to the level after the 3
rd
baseline night [Chi-square (6)=11.9, p=0.07]. IGF-1 increased
significantly afterthefirst recoverynight compared tobaseline [Chi-
square (6)=13.2, p=0.03] and to the concentration after the 3
rd
baseline night [Chi-square (6)=13.92, p=0.03].
Materials and Methods
Ethics statement
The protocol was approved by the Ethics Committee of the
ISPPC Hospital and all volunteers gave their written informed
consent. The volunteers received financial compensation for their
participation in the study.
Table 1. Sleep architecture at baseline and during sleep restricted and recovery nights.
Baseline Restriction 1 Restriction 2 Restriction 3 Restriction 4 Restriction 5 Recovery 1 Recovery 2 Recovery 3 P Value
Stage 1
(min)
8.7
(6.1-12.0)
8.0
(3.5-10.5)
3.5
(1.5-6.5)
2.0
(1.5-5.0)
2.5
(2.0-7.0)
3.0
(1.5-8.5)
5.5
(1.5-8.5)
9.5
(7.0-14.5)
5.0
(3.2-13.5)
0.17
Stage 2
(min)
169.7
(159.5-215.5)
94.5
*
(86.0-112.5)
85.5
*
(68.0-111.0)
100.5
*
(85.5-115.5)
93.0
*
(66.5-114.0)
114.5
*
(89.0-124.5)
165.0
(124.5-205.5)
190.0
(173.5-224.5)
196.0
(155.2-211.7)
, 0.001
SWS
(min)
124.0
(99.0-152.6)
121.5
(91.5-141.0)
119.0
(87.5-142.0)
115.0
(98.0-126.0)
117.5
(94.0-132.0)
110.0
(95.0-122.0)
163.0
*
(124.0-198.5)
129.5
(102.5-160.5)
137.5
(95.0-152.0)
0.01
REM
(min)
100.0
(87.6-109.25)
43.0
*
(38.5-52.5)
51.5
*
(50.0-70.0)
62.0
*
(40.0-71.5)
53.5
*
(46.5-70.5)
67.0
*
(59.0-72.5)
102.5
(76.5-113.0)
97.5
(87.5-112.0)
89.0
(62.7-116.2)
, 0.001
Stage 1
(%)
2.1
(1.4-2.9)
2.9
(1.4-3.8)
1.3
(0.5-2.4)
0.7
(0.5-1.8)
2.5
(0.7-2.4)
1.0
(0.5-2.3)
1.2
(0.4-1.9)
2.2
(1.6-3.1)
1.4
(0.8-3.3)
0.12
Stage 2
(%)
47.0
(38.5-51.2)
34.7
*
(34.1-40.5)
31.9
*
(24.8-41.8)
37.1
*
(33.5-41.5)
32.8
*
(23.9-41.9)
43.0
(30.5-45.0)
36.9
(31.5-45.0)
42.9
(38.7-51.5)
45.3
(38.1-52.1)
0.01
SWS
(%)
27.7
(22.9-35.0)
45.5
*
(35.2-47.4)
45.7
*
(32.1-50.2)
43.0
*
(39.5-47.3)
41.9
*
(35.4-46.3)
39.4
(35.5-50.8)
36.3
(31.5-44.4)
29.8
(23.3-35.6)
33.1
(22.9-40.7)
0.03
REM
(%)
24.2
(21.4-25.9)
16.4
*
(15.2-18.7)
19.3
(17.9-25.2)
23.0
(16.1-25.9)
19.5
(16.7-25.3)
24.4
(20.2-25.7)
22.6
(16.6-29.7)
22.2
(19.7-26.0)
21.2
(14.4-22.4)
0.02
Sleep
efficiency (%)
88.7
(85.3-90.6)
88.1
(84.1-93.8)
91.3
(89.1-93.6)
93.6
*
(88.9.-95.6)
94.3
*
(93.0-95.6)
95.9
*
(93.4-98.0)
93.4
*
(92.1-95.0)
90.8
(89.0-94.8)
88.3
(86.5-90.5)
0.004
Total sleep time
(min)
419.3
(396.0-421.2)
267.0
*
(252.0-280.0)
272.0
*
(260.5-280.0)
275.0
*
(273.5-284.0)
280.0
*
(252.0-280.0)
279.5
*
(271.0-288.0)
452.0
*
(444.0-456.2)
435.5
(427.0-454.0)
418.5
(403.0-425.0)
0.003
Values are shown as medians (25%–75% range). Baseline (average of the 3 baseline nights for each volunteer) was used as control and other nights as the comparative
groups. Data comparisons with the baseline were performed using a Friedman Repeated Measures Analysis of Variance on Ranks and a Dunn’s post-hoc test.
*Significant difference vs. baseline (P,0.05).
doi:10.1371/journal.pone.0028230.t001
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Nine healthy male non-smokers (aged 22–29 years, body mass
index between 19 and 25) without neurological, psychiatric,
cardiac, or endocrine disease participated in the experiment. The
volunteers did not drink alcohol on a regular basis and were not
taking any drugs. Each volunteer underwent a rigorous medical
evaluation that included psychiatric and medical histories and
screening laboratory tests (complete blood cell count, routine
chemistry panel, and lipid profile). No sleep complaints were
reported and sleep disorders were excluded on the basis of an
interview and one night of polysomnographic recording.
Experimental procedure
After two weeks of regular sleep-wake behavior with 8 h of sleep
per night documented by actigraphic recordings and sleep diaries,
the volunteers were admitted to the Sleep Laboratory for eleven
nights and days. The study consisted of three baseline nights
(sleeping from 11 pm to 7 am), five sleep restricted nights, during
which sleep was allowed only between 1 am and 6 am, and three
recovery nights of 8 hours sleep (11 pm to 7 am). During the study,
the subjects were closely supervised and intake of any medication,
alcohol, or xanthine derivatives (coffee, tea, chocolate, cola) was
prohibited. Subjects received standard hospital meals of a
maximum of 2500 calories/day with comparable proportions of
nutrients (protein, fats, carbohydrates) across days and sessions.
Controlled drinks and snacks were available during the sleep
restricted nights until 11 pm. To monitor the state of alertness of
the subjects and to ensure no sleep episodes occurred outside the
permitted hours, continuous EEG, electrooculogram and electro-
myogram recordings were performed with an ambulatory device
(DreamH, Medatec, Brussels, Belgium) with the following EEG
derivations (C4/A1, C3/A2, O2/A1, O1/A2 F4/A1, F3/A2).
During the study, volunteers were free to move within the unit
carrying this ambulatory device, which was also used for the night
recordings. Sleep recordings were scored visually in all subjects
according to Rechtschaffen and Kales [9].
Blood parameters
Fasting blood samples were obtained from an antecubital vein
at 7:00 am after the 1
st,2
nd and 3
rd baseline nights, after the 1
st,
3
rd and 5
th restricted nights, and after the 1
st,2
nd and 3
rd nights
of sleep recovery with the volunteers comfortably seated in an
armchair. Whole blood was collected in EDTA-treated tubes;
serum samples were collected in vacuum tubes without
anticoagulant; plasma samples were harvested in citrated vacuum
tubes. CRP and apolipoprotein B (ApoB) were evaluated on
SYNCHRON LXH. Fibrinogen was determined on a STAH
automate (Stago, Parsippany, NJ). Leukocyte counts and subsets
were determined on a CELL-DYN4000H hemocytometer
(Abbott, Abbott Park, IL). The antibodies used for the
measurement of Mox-LDL have been characterized previously
[25]. Serum IL-8 concentrations were quantified using an ELISA
test (Becton DickinsonH, Franklin Lakes, NJ) as were plasma
MPO levels (ZentechH, Angleur, Belgium) and insulin-like growth
factor (IGF)-1 levels (Diagnostic Systems Laboratories, Sinsheim,
Germany).
Statistics
Data were analyzed using the SigmaStatH 3.5 software
(SystatH, San Jose, CA). Median values with range (25%–75%)
are given because the data were not normally distributed
(Kolmogorov-Smirnov) and we therefore used non-parametric
tests with the Friedman Repeated Measures Analysis of Variance
on Ranks test, which includes a chi-square test, being the most
appropriate for our study design. This test displays the results of
the chi-square, degrees of freedom and p value. The baseline
Table 2. Immune and inflammatory blood markers at baseline, and during sleep restriction and recovery periods.
Baseline Restriction 1 Restriction 3 Restriction 5 Recovery 1 Recovery 2 Recovery 3 P Value
Leukocytes
(10
3cells/ml)
6.77
(5.58-7.32)
7.2
(5.92-7.85)
6.86
(6.47-7.43)
7.40
(6.30-8.22)
7.10
(5.95-7.76)
6.50
(6.07-8.30)
6.70
(5.97-7.90)
0.36
Neutrophils
(10
3cells/ml)
3.56
(2.66-4.13)
3.76
(2.96-4.63)
3.72
(3.34-4.02)
3.96
(3.28-4.34)
3.58
(3.21-4.05)
3.79
(2.70-4.57)
3.42
(2.97-4.45)
0.19
Lymphocytes
(10
3cells/ml)
2.42
(2.27-2.64)
2.35
(1.93-2.59)
2.34
(2.1-2.5)
2.44
(2.0-2.6)
2.56
(2.3-2.7)
2.37
(2.1-4.1)
3.3
(2.6-4.1)
0.62
Monocytes
(10
3cells/ml)
0.55
(0.49-0.62)
0.61
(0.53-0.72)
0.56
(0.51-0.68)
0.61
(0.51-0.72)
0.57
(0.52-0.66)
0.65
(0.49-0.74)
0.65
(0.50-0.71)
0.18
Fibrinogen
(mg/dl)
2.76
(2.49-2.98)
2.95
(2.71-3.07)
2.78
(2.54-2.98)
2.71
(2.41-2.94)
2.72
(2.39-2.99)
2.74
(2.47-2.95)
2.90
(2.44-3.18)
0.13
Hs-CRP
(mg/dl)
0.09
(0.07-0.11)
0.10
(0.06-0.14)
0.08
(0.06-0.09)
0.08
(0.05-0.09)
0.08
(0.06-0.09)
0.06
(0.06-0.09)
0.07
(0.05-0.11)
0.11
Interleukin-8
(pg/ml)
4.70
(4.34-6.00)
6.36
(4.33-6.00)
4.78
(3.39-5.86)
4.68
(4.03-6.91)
5.88
(4.59-9.61)
6.60
(3.75-10.457)
4.36
(3.61-5.48)
0.11
ApoB (mg/dl) 74.1
(71.7-89.4)
72.9
(68.1-93.7)
71.6
(64.4-93.2)
68.5
(64.0-85.6)
68.9
(64.5-85.9)
73.1
(63.0-86.7)
66.1
*
(64.0-84.9)
0.007
Mox-LDL
(mg/ml)
8.1
(3.35-11.50)
12.3
*
(4.51-28.19)
14.6
*
(4.47-23.03)
10.3
(4.40-11.92)
9.2
(3.51-12.73)
8.8
(3.47-14.19)
6.8
(4.87-11.11)
0.002
IGF-1
(pg/ml)
0.95
(0.72-1.09)
0.88
(0.69-1.23)
0.97
(0.66-1.40)
0.95
(0.76-1.22)
1.18
*
(0.83-1.38)
0.92
(0.80-1.16)
0.87
(0.80-1.08)
0.03
Values are shown as medians (25%–75% range). Baseline (average of the 3 baseline days for each volunteer) was used as control and other days as the comparative
groups. Data comparisons with the baseline were performed using a Friedman Repeated Measures Analysis of Variance on Ranks and a Dunn’s post-hoc test.
*Significant difference vs. baseline (P,0.05).
doi:10.1371/journal.pone.0028230.t002
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volunteer) or the 3
rd baseline values were used as the control and
other days as the comparative groups. Data comparisons with the
baseline or the 3
rd baseline values were performed using a Dunn’s
post-hoc test. A probability level of p,0.05 was considered
statistically significant.
Discussion
Our main findings were that Mox-LDL concentrations
increased during chronic restricted sleep, indicating oxidative
stress, and MPO concentrations peaked after the first recovery
night. Moreover, there was a significant rebound of SWS during
Figure 1. Myeloperoxidase (MPO)-modified low-density lipoprotein/apolipoprotein B (Mox-LDL/ApoB) ratio (A) and MPO (B) at
baseline, and during sleep restriction and recovery periods. Values are shown as medians (25%–75% range). Baseline (average of the 3
baseline days for each volunteer) was used as control and other days as the comparative groups. Data comparisons with the baseline were performed
using a Friedman Repeated Measures Analysis of Variance on Ranks and a Dunn’s post-hoc test. * Significant difference vs. baseline (P,0.05).
doi:10.1371/journal.pone.0028230.g001
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control group would certainly have improved the protocol design,
there was good reproducibility of all measured blood and sleep
parameters during the baseline nights indicating that they were
not significantly influenced by the presence of the volunteers in
the sleep laboratory. Moreover, when we compared the restriction
and recovery night values with values from the 3
rd baseline night
(with the first two baseline nights then considered as allowing
participants to adapt to the laboratory setting as adaptation
nights), the results were similar to those obtained using the average
of the 3 baseline night values as the comparator.
Many studies have suggested that sleep duration plays a
significant role in CVD [10–12]; however, the mechanisms
involved have not been clearly elucidated. Epidemiological studies
have identified a link between leukocyte counts and an increased
risk of CVD [13]. Within the leukocyte sub-population, monocytes
[14] and neutrophils [15] may influence the development of
coronary heart disease through their ability to cause proteolytic
and oxidative damage to coronary arteries. We previously
observed in postmenopausal women that sleep restriction to four
hours of sleep for three consecutive nights was associated with
increased leukocyte, monocyte, and neutrophil counts, and total
cholesterol and LDL-cholesterol (LDL-c) [16]. In a second study,
using the same sleep restriction protocol but in healthy young men,
only the neutrophil count was increased suggesting that sex
differences may be a potential confounding factor on the effects of
chronic sleep restriction although the age difference between the
two studies also needs to be taken into account [17]. In the present
study, there was a small but non-significant increase in neutrophil
count during the sleep restricted days. Our previous results
suggested that neutrophil count could be a very sensitive, early
immunological marker of sleep loss, and may reflect the sleep debt
[18]. Accordingly, the neutrophil response may be proportional to
the intensity of sleep restriction. The moderate degree of sleep
restriction in the present study was likely insufficient to cause the
significant increase in neutrophil count that we previously
observed in more severe, acute sleep restriction protocols [4,17].
Similar to our present and earlier observations [16,17], Haack
et al [19] reported no significant change in hs-CRP levels after
chronic sleep restriction with 12 consecutive days of 4 hours sleep
per night. In contrast, Meier-Ewert et al. [20] observed an increase
in hs-CRP levels during chronic sleep restriction of 4.2 hours per
night for 10 days and after 88 hours of total sleep deprivation, and
Frey et al. [21] reported a decrease in hs-CRP following one night
of total sleep deprivation. Multiple blood samplings measured
from an indwelling catheter were not performed to avoid any
confounding effects of local inflammation from the blood drawing
procedure as has previously been reported in the production of
local inflammatory cytokines [22]. Potential confounding effects
of a circadian shift could, therefore, have contributed to the
unchanged hs-CRP we observed with a single daily blood sample,
but hs-CRP protein levels have been described as being relatively
stable over a 24-hour period and not displaying a circadian
rhythm [23]. The reasons for the apparent discrepancies between
our study and other similar chronic sleep restriction studies,
including that by van Leeuwen et al. [3], are not clear. Some
potentially causative differences between our two protocols remain
in terms of the greater intensity of the sleep restriction in the study
by van Leeuwen at al. (4 hours of sleep for 5 consecutive nights), as
well as the timing of the restriction period. Nevertheless, both
studies reported increases in the cardiovascular risk biomarkers,
i.e., hs-CRP and MPO, which persisted or peaked after the
recovery nights. An additional potential confounding factor could
be that during the sleep restricted phase, blood was sampled after
subjects had been awake for 1 hour, whereas during baseline
periods, blood was sampled right after waking the subjects. An
argument suggesting that this factor did not significantly influence
the levels of Mox-LDL production and MPO levels is that there
was no change in MPO or ApoB (the protein modified by the
MPO) levels between the baseline nights (blood sampling at 7 am
right after waking) and the restriction phase (blood sampling at 7
am, 1 hour after waking). A slight decrease in ApoB (previously
reported to display low diurnal variability) was measured during
the recovery period, possibly induced by the rise in blood IGF-1, a
negative regulator of ApoB expression in healthy men [24,25].
During our study, there was a temporal discordance between the
Mox-LDL/ApoB ratio and the increase in MPO concentrations.
Indeed, the Mox-LDL/ApoB ratio increased after the first night of
sleep restriction in contrast to MPO, which increased after the first
recovery night.Thecapture antibodywe used forthisanalysisreacts
only with LDL modified by the MPO-H2O2-Cl
2 system [26].
Previously, we showed that the membrane-bound nicotinamide-
adenine-dinucleotide phosphate (NADPH) oxidase of endothelial
cells played a central role in Mox-LDL production, even at constant
MPO concentrations [27]. The O
2
2 generated by membrane
NADPH oxidase is the starting substrate for MPO to catalyze the
production of H2O2 to form HOCl. Catecholamines have been
shown to activate NADPH-dependent vascular oxidases [28]. Irwin
et al [29] reported that loss of sleep or disordered sleep increased
blood catecholamine concentrations, suggesting that this mecha-
nism could be one explanation for the increased Mox-LDL during
sleep restriction without changes in MPO. Of interest is the increase
in the Mox-LDL/ApoB ratio range during the restriction phase.
This may suggest that some subjects are more sensitive than others
to the sleep restriction procedure. In addition, why did the Mox-
LDL/ApoB ratio decrease at the end of the sleep restriction phase?
One explanation could be that the modified LDL increases the
expression of scavenger receptors inducing a secondary clearance of
Mox-LDL from the blood as previously demonstrated [30].
Our results showed that the first recovery night was associated
with an increased amount of SWS, concomitant with the presence
of a peak in MPO level. We can only speculate on the reasons
underlying this observation. Spiegel et al [31] reported a tight
association between the amount of growth hormone secreted and
the amount of SWS during sleep recovery. Secreted growth
hormone stimulates production by the liver of circulating blood
IGF-1 which displays immune and inflammatory regulatory
properties [32,33]. IGF-1 is able to induce degranulation of azuro-
philic granules (the MPO content) by peripheral blood mononu-
clear cells [34]. Van Leeuwen et al. [35] reported that the recovery
period following chronic sleep restriction was associated with a
significant increase in serum IGF-1 concentrations. We also
observed a significant IGF-1 peak after the first recovery night,
which may, in part, explain the peak in MPO seen after this
recovery night.
What could be the biological effects of the variations in MPO
and Mox-LDL? Clinical studies have reported associations
between blood MPO levels and increased cardiovascular events
[7,36]. In our study, an increase was observed only after the first
recovery night but potentially inducing a short-term oxidative
effect. Indeed, we previously showed that MPO increased
production of reactive oxygen species (ROS) on endothelial cells
after 30 min of exposure [37]. In another study, we demonstrated
that, in contrast to copper–oxidized LDLs (ox-LDL), Mox-LDL
(more physiologically relevant) induced a greater production of
ROS on human monocytes after 6 hours of exposure [38]. Only
Mox-LDL-induced ROS production was dependent on cytosolic
phospholipase A2.
Sleep Restriction/Recovery and Cardiovascular Risk
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e28230In conclusion, our results show for the first time that the
recovery process after chronic sleep restriction is coupled to
changes in blood biomarkers that have been associated with
cardiovascular risk. Further sleep studies that modulate the
intensity and duration of the sleep restriction and recovery
processes are required to better understand this phenomenon. An
additional issue that needs further investigation is whether there is
a difference in the response of cardiovascular risk markers to sleep
restriction in men and women. Sex-specific differences in the
inflammatory response were reported in a laboratory study
following one night of partial sleep loss in same age populations
[39]. Emerging evidence from epidemiological studies also
indicates that women may have different chronic responses to
sleep duration compared to men, and our data need, therefore, to
be confirmed in women [40].
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